Featured

CD8s get by without a little help from their friends

During acute infections, the primary immune response depends on CD4+ T cells providing help to CD8+ T cells. However, many effector CD8+ T cells (Teff) can respond to pathogens independently of helper responses, but these cells respond poorly to...

A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis

Qian and Ma et al. fused TFF2, a partial CXCR4 agonist, with murine serum albumin (MSA) to develop TFF2–MSA peptides that restore anti-PD-1 sensitivity in syngeneic gastric cancer (GC) tumor models. ...

Regulatory T cells define affinity thresholds for CD8+ T cell tumor infiltration

Mohsen et al. showed that a low-affinity LCMV p33-derived A4Y peptide linked to a bacteriophage Qβ virus-like particle induced a robust and specific T cell response, but showed limited cross-reactivit...

Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas

Labiano et al. showed that in mice with diffuse midline glioma (DMG), intratumoral co-administration of the Delta-24-RGD oncolytic virus and agonist CD40 antibodies extended survival and induced compl...

In vivo CAR T cell generation to treat cancer and autoimmune disease

Hunter et al. developed LNPs for in vivo i.v. CAR delivery, with reduced liver tropism and superior tolerability in rats and non-human primates (NHP) compared to Pfizer’s COVID vaccine formulation. In...

See all for this week

Previous Digests

PSGL-1: a novel immune checkpoint for phagocytosis

June 25, 2025

Tumor cells can evade immune detection through a wide range of mechanisms, not all of which are fully understood. In recent work by Zhong and Wang et al., P-selectin glycoprotein ligand 1 (PSGL-1) – a known molecule involved in...

Dimming IFN signaling to brighten CAR-T persistence and efficacy

June 18, 2025

While CAR T cell therapy has shown great success in hematological cancers, relapses may occur, and the therapy has so far shown limited efficacy in solid tumors. Based on their previous data, which showed that genetic deletion of IFNγ...

A new off-the-shelf CAR T cell product made from iPSCs

June 11, 2025

CAR T cell therapies are well known for their potent capacity for killing antigen-expressing target cells. However, they are often hindered by factors in solid tumors and by challenges related to the development of an autologous T cell product...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials